Dementia is a major cause of disability in the later stages of life.¹ Hallucinations and/or delusions, two of the neuropsychiatric symptoms of dementia,² are associated with worse patient outcomes, including institutionalization and death.³ There are no FDA-approved atypical antipsychotics for the treatment of dementia-related psychosis,⁴ and clinical compendia recognized by CMS do not recognize the use of atypical antipsychotics as medically acceptable treatment for dementia-related psychosis.⁵

A recent AJMC^® Clinical Practice Brief explores the critical unmet need for effective pharmacologic therapy for dementia-related psychosis. An expert interview with George T. Grossberg, MD, the Samuel W. Fordyce Professor and director of geriatric psychiatry in the Department of Psychiatry and Behavioral Neuroscience at Saint Louis University School of Medicine in Missouri, is included, in which Dr. Grossberg discusses the burden of dementia and dementia-related psychosis on patient outcomes, caregivers, and the health care system.

To access the publication, "The Impact and Unmet Needs Associated With Dementia-Related Psychosis," please visit www.ajmc.com or click on the image below.

 

{{Follow Up/ Meeting Request}}

{{Closing}},

{{userName}}
{{User.Title}}
{{User.Phone}}
{{User.Email}}

References:

1. Alzheimer’s Disease International. World Report 2009. Accessed October 2, 2020.
https://www.alz.co.uk/research/world-report-2009
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). 5th ed. American Psychiatric Publishing; 2013.
3. Scarmeas N, Brandt J, Albert M, et al. Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch Neurol. 2005;62(10):1601-1608. doi:10.1001/archneur.62.10.1601
4. FDA issues public health advisory for antipsychotic drugs used for treatment of behavioral disorders in elderly patients. News release. FDA; April 11, 2005. http://psychrights.org/drugs/ANS01350.html
5. CMS. Chapter 6–Part D Drugs and formulary requirements. Medicare Prescription Drug Benefit Manual. CMS; January 15, 2016. Accessed October 22, 2020. https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/Part-D-Benefits-Manual-Chapter-6.pdf

 
Acadia Pharmaceuticals Inc. 12830 El Camino Real, Suite 400, San Diego, CA 92130
Unsubscribe

©2020 Acadia Pharmaceuticals Inc.
Acadia is a registered trademark of Acadia Pharmaceuticals Inc.
All rights reserved. DRP-0323 11/20